Welcome to our dedicated page for Quantum BioPharma SEC filings (Ticker: QNTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the science and the strategy inside Quantum BioPharma disclosures can feel like decoding two companies at once. The 200-page annual report details proprietary myelin-repair research while dozens of 8-K updates flag shifts in its real-estate-backed investment arm. If you’ve ever asked, “What does Quantum BioPharma report in their SEC filings?” or hunted for a single trial milestone among footnotes, you know the challenge.
Stock Titan solves that problem by pairing real-time EDGAR feeds with AI that translates every section into plain English. Whether you need the Quantum BioPharma quarterly earnings report 10-Q filing or want Quantum BioPharma Form 4 insider transactions real-time, our dashboard highlights the numbers that move the stock. Key documents are linked with short, shareable summaries so Quantum BioPharma SEC filings explained simply stay accurate. You’ll see at a glance how cash from strategic investments funds Phase-2 trials, what the latest Quantum BioPharma 8-K material events explained mean for risk, and how R&D spending trends quarter over quarter.
- AI-powered summaries of 10-K, 10-Q, and 8-K
- Real-time Quantum BioPharma insider trading Form 4 transactions alerts
- Side-by-side financial and R&D trend analysis
- Instant download of all exhibits and XBRL data
Still digging deeper? Activate comparison tools for Quantum BioPharma annual report 10-K simplified, generate a Quantum BioPharma earnings report filing analysis, or set alerts for Quantum BioPharma executive stock transactions Form 4. We also surface voting matters in the Quantum BioPharma proxy statement executive compensation so institutions can model dilution before it happens. By understanding Quantum BioPharma SEC documents with AI, analysts monitor pipeline progress, insider sentiment, and capital allocation—without wading through legalese.
Malone Wealth Ventures LLC reports beneficial ownership of 1,047,155 common shares of Quantum Biopharma Ltd., equal to 27.4% of the class. The filer discloses sole voting power for 104,289 shares and sole dispositive power for 1,047,155 shares. The filing is made on Schedule 13G (Amendment No. 7) indicating a passive reporting status and states that shares were acquired and are held in the ordinary course of business, not to influence control. The filing lists U.S. addresses for Malone Wealth Ventures LLC and the issuer’s Toronto executive office.
Malone Wealth Ventures LLC, a U.S. registered investment adviser, filed Schedule 13G/A (Amendment No. 5) on 10 July 2025 disclosing a significant position in Quantum Biopharma Ltd. (QNTM). The firm reports beneficial ownership of 735,148 Class B subordinate voting shares, equating to 19.4 % of the outstanding class. Malone retains sole voting power over 103,601 shares and sole dispositive power over the full stake; no shares are subject to shared voting or dispositive power. The difference indicates that most shares are held for advisory clients who keep voting rights while Malone manages disposition.
The filer certifies the shares were acquired in the ordinary course of business and not to influence control. No subsidiaries or group members are involved, and no single client holds more than 5 % of the class. Quantum Biopharma’s headquarters remain at 55 University Ave., Suite 1003, Toronto, Ontario.
This near-20 % holding positions Malone as a major stakeholder, improving institutional visibility for Quantum Biopharma and potentially stabilising the shareholder base. Investors should monitor upcoming ownership updates, as any move above the 20 % threshold or a switch to Schedule 13D could signal a change in strategic intent.
FAQ
What is the current stock price of Quantum BioPharma (QNTM)?
What is the market cap of Quantum BioPharma (QNTM)?
